Amgen added to uncertainty surrounding the OX40 drug class by returning an autoimmune candidate to Kyowa Kirin. | Amgen added ...
Roche is continuing its return to the RNA space by paying $200 million for the worldwide license to one of SanegeneBio’s ...
Pharmaceutical Technology on MSN
SanegeneBio and Genentech sign $1.5bn global RNAI licensing deal
The deal provides SanegeneBio with an upfront payment of $200m.
Under the agreement, SanegeneBio has granted Genentech exclusive worldwide rights to develop and commercialize the undisclosed program.
SanegeneBio and Genentech entered a global licensing agreement aimed at advancing an RNA interference (RNAi) therapeutic ...
Genentech Inc. is paying $200 million up front and up to $1.5 billion in milestone payments to license one of Suzhou Sanegene Bio Inc.’s RNAi programs. Metabolic and autoimmune-focused Sanegene did ...
SanegeneBio grants exclusive worldwide license to one of its RNAi programs to Genentech - SanegeneBio to receive $200 million ...
Discover how a newly developed platform technology from The University of North Carolina at Chapel Hill can enhance RNAi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results